Propanc Biopharma, Inc. (PPCB)
| Market Cap | 57.68M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -55.40M |
| Shares Out | 12.76M |
| EPS (ttm) | -51.96 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 25,327,453 |
| Open | 4.905 |
| Previous Close | 3.670 |
| Day's Range | 4.240 - 5.690 |
| 52-Week Range | 0.000 - 145.460 |
| Beta | 19,200.53 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Sep 30, 2025 |
About PPCB
Propanc Biopharma, Inc., a development-stage biopharmaceutical healthcare company, engages in the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancers in Australia. Its lead product candidate is PRP, an intravenous injection proenzyme treatment designed as a therapeutic option in cancer treatment and prevention which has completed pre-clinical studies. The company has a research and collaboration agreement with the University of Jaén, to undertakes the research activities for the POP1 Program and the Un... [Read more]
Financial Performance
Financial StatementsNews
Propanc Biopharma Announces Closing of Public Offering and Uplisting to NASDAQ
MELBOURNE, Australia, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients...
U.S. IPO Weekly Recap: Bullish And Miami International Complete The Last Major IPOs Of The Summer
Eight issuers listed in the US this past week, six of which were eligible for inclusion in our IPO stats, joined by two SPACs. There are no IPOs currently scheduled for the week ahead, though some sma...
Propanc Biopharma Announces Nasdaq Uplisting and Pricing of $4 Million Public Offering
MELBOURNE, Australia, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patien...